Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Investor Overview

News Releases

29 Oct '24
   – Evaluation of real-world trends and outcomes in hospitalized U.S. HRS-AKI patients treated with TERLIVAZ – DUBLIN , Oct. 29, 2024 /PRNewswire/ --  Mallinckrodt plc , a global specialty pharmaceutical company, today announced a poster presentation on TERLIVAZ ® (terlipressin) for injection in
24 Oct '24
DUBLIN , Oct. 24, 2024 /PRNewswire/ -- Mallinckrodt plc  ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that it will report third quarter 2024 earnings results for the period ended September 27, 2024, on Tuesday, November 5, 2024 .      A conference
go back to the top of the page